Status:
COMPLETED
Aripiprazole in Adolescents With Schizophrenia
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
13-17 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.
Eligibility Criteria
Inclusion
- Primary diagnosis of Schizophrenia 1
Exclusion
- Patients diagnosed with schizoaffective disorder, major depressive disorder, delirium, or bipolar disorder
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT00102063
Start Date
July 1 2004
End Date
August 1 2006
Last Update
August 10 2012
Active Locations (55)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Birmingham, Alabama, United States
2
Local Institution
Little Rock, Arkansas, United States
3
Local Institution
Costa Mesa, California, United States
4
Local Institution
Los Angeles, California, United States